Effect of oral tablet nebivolol on improving the inner lining of blood vessels

Phase 4

• Conditions: Health Condition 1: null- Patients with endothelial dysfunction and coronary artery disease

• Registration Number: CTRI/2012/01/002384
• Lead Sponsor: JIPMER

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

1.Age - 18-75 years

2.Either sex

3.Angiographically proven coronary artery stenosis with >50% block in atleast one of the major arteries or History of acute coronary syndrome

4. Known case of Hypertension

Exclusion Criteria

1.Patients with history of acute coronary syndrome in the preceding three months.

2.Patients already on nebivolol for BP control

3.Uncontrolled hypertension with SBP > 180mm Hg or DBP >90mmHg

4.Patients with left ventricular ejection fraction <35%

5.Patients with coexisting medical illnesses which can interfere with assessment of outcomes

6.Known history of hypersensitivity reaction to nebivolol

7.Pregnant women and lactating women

8.Patients having coexisting illness which are a contra-indication to beta blocker therapy such as asthma, sick sinus syndrome, peripheral vascular disease, variant angina.

9.Marked dyslipidemia

10.Patients unwilling to participate in the study

11.Past history of liver disease, known case of alcohol abuse, or Elevated liver enzymes defined as ALT, AST or ALP greater than thrice the upper limit of normal.

Study & Design

• Study Type: Interventional
• Study Design: Not specified